Who Owns Yunnan Baiyao Group Company?

Yunnan Baiyao Group Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Yunnan Baiyao Group Company?

Understanding the ownership structure of a company is key to grasping its strategic direction and market influence. Yunnan Baiyao Group Co., Ltd. has undergone significant transformations, moving from a state-controlled entity to a more diversified shareholding enterprise through mixed-ownership reforms. Founded in 1902 by Qu Huanzhang, the company's roots are deeply embedded in traditional Chinese medicine, with its initial focus on a renowned hemostatic powder.

Today, Yunnan Baiyao Group (SZSE: 000538) is a major player in China's pharmaceutical sector, involved in R&D, manufacturing, and sales of both traditional Chinese medicine and modern pharmaceuticals. The company has expanded its reach into health products and personal care, notably with items like toothpaste, capitalizing on its strong brand and natural ingredient expertise. As of July 3, 2025, its market capitalization stands at approximately CN¥99 billion, reflecting its substantial market presence. In 2024, the company reported a net profit attributable to shareholders of 4.75 billion yuan, a 16% increase, with revenue growing 2% to 39.98 billion yuan.

Delving into the ownership of Yunnan Baiyao reveals a fascinating journey. Initially established by its founder, the company's ownership has evolved considerably over time. The current landscape of Yunnan Baiyao ownership is shaped by a complex interplay of stakeholders, including state-owned entities and public shareholders. This evolution is crucial for anyone looking to understand the dynamics behind this prominent pharmaceutical firm.

The question of who owns Yunnan Baiyao Group is central to understanding its governance and future direction. While it is a publicly traded company, making its stock available to a wide range of investors, its history as a state-backed enterprise means that state interests often play a significant role. Examining the Yunnan Baiyao stock ownership reveals a blend of institutional investors, individual shareholders, and potentially state-affiliated entities. The Yunnan Baiyao Group owner is not a single individual but rather a collective of shareholders whose holdings influence the company's decisions. The Yunnan Baiyao company structure reflects this mixed ownership, with a board of directors overseeing its operations, tasked with balancing the interests of all shareholders.

The ownership history of Yunnan Baiyao is marked by key reforms that have shaped its current status. Understanding if Yunnan Baiyao is a state-owned enterprise in the traditional sense requires looking at the controlling shareholder and the extent of state influence. The major shareholders of Yunnan Baiyao Group are critical to identifying the ultimate control. The Yunnan Baiyao Group owner, in terms of controlling stake, is a key piece of information for investors. The registered capital of Yunnan Baiyao supports its extensive operations, which span various subsidiaries and product lines, including well-known items like Yunnan Baiyao Group BCG Matrix. The business scope of Yunnan Baiyao Group is broad, encompassing pharmaceuticals and health products.

The management of Yunnan Baiyao Group is overseen by its board, with the CEO playing a crucial role in day-to-day operations. The market capitalization of Yunnan Baiyao highlights its economic significance. The company's financial performance in 2024, with a notable increase in net profit and revenue, indicates a healthy business. The subsidiaries of Yunnan Baiyao Group contribute to its diversified portfolio, strengthening its market position. The founding of Yunnan Baiyao Group by Qu Huanzhang laid the groundwork for its enduring legacy in traditional Chinese medicine.

The origins of the company trace back to 1902, with its founder, Qu Huanzhang, a practitioner of traditional Chinese medicine. Hailing from Jiangchuan County in Yunnan Province, Qu Huanzhang dedicated himself to exploring and studying numerous herbs. This extensive research led him to formulate a potent remedy, initially known as 'Qu Huanzhang Panacea' or 'Qu Huanzhang Baibao Dan,' which would later gain widespread recognition as Yunnan Baiyao. His ambition was to create a powerful medicine with significant hemostatic, analgesic, and anti-inflammatory properties, a formulation that quickly earned it the moniker of a 'miracle remedy.'

Initially, the ownership of this unique medicine was entirely private, residing with its creator, Qu Huanzhang. However, a significant transformation in its ownership structure occurred after Qu's passing. In 1956, his wife, Liao Lanying, made a momentous decision to donate the secret prescription for Yunnan Baiyao to the Chinese government. This act was pivotal, marking the transition of the proprietary formula into state control and setting the stage for its large-scale production.

Following this transfer, the Yunnan Baiyao Factory was officially established in 1971 by the Yunnan provincial government. The primary objective behind its establishment was the mass production of the now-famous powder. This development effectively positioned the enterprise as a state-owned entity from its formal industrial inception, aligning with the economic policies prevalent in China at the time, which favored direct government control over strategic industries. It is important to note that specific details regarding early equity splits or investor involvement prior to 1956 are not publicly available, as the formula and its initial production were under the founder's personal purview.

Founder's Legacy

Yunnan Baiyao was founded in 1902 by Qu Huanzhang, a dedicated Chinese medicine practitioner.

The Secret Formula

Qu Huanzhang developed the renowned 'Qu Huanzhang Panacea,' later known as Yunnan Baiyao, after extensive herbal research.

Transition to State Ownership

In 1956, Qu Huanzhang's wife, Liao Lanying, donated the secret prescription to the Chinese government.

Establishment of Production

The Yunnan Baiyao Factory was established in 1971 by the Yunnan provincial government for mass production.

Early Ownership Structure

Early ownership was private with the founder; post-donation, it transitioned to state control.

State-Owned Enterprise

The company became a state-owned entity from its formalized industrial inception in 1971.

The early history of the company reveals a clear trajectory from private innovation to state-controlled production, a common pattern for significant industries in China during that era. The founder's dedication to medicinal research laid the groundwork for a product that would become a national treasure, and his family's decision to entrust the formula to the government ensured its widespread availability and development. This historical context is crucial for understanding the current Yunnan Baiyao ownership landscape and its position as a major player in the pharmaceutical sector. Understanding the Revenue Streams & Business Model of Yunnan Baiyao Group provides further insight into its operational framework.

Key Takeaways on Early Ownership

The foundational period of the company highlights a significant shift in ownership, moving from an individual's private enterprise to a state-managed entity.

• Founder: Qu Huanzhang, a Chinese medicine practitioner.
• Origin Year: 1902.
• Original Name: 'Qu Huanzhang Panacea' or 'Qu Huanzhang Baibao Dan'.
• Key Transition: Donation of the secret prescription by Liao Lanying (Qu's wife) to the government in 1956.
• Formal Establishment: Yunnan Baiyao Factory established in 1971 by the Yunnan provincial government.
• Ownership Status: Transitioned to state-owned from its industrial inception.

Yunnan Baiyao Group SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Yunnan Baiyao Group Co., Ltd. (SZSE: 000538) began its journey as a publicly traded entity with its IPO on December 15, 1993. For a considerable period, it operated as a state-owned enterprise (SOE), reflecting significant government influence. A pivotal shift in its ownership occurred between 2016 and 2017 with the implementation of 'mixed-ownership reform,' designed to integrate private investment and bolster corporate governance.

This reform initiative saw the introduction of New Huadu Industrial Group as a strategic investor in 2016. Through a capital injection of approximately 25.4 billion yuan into Baiyao Holdings, the parent company, both Yunnan SASAC and New Huadu each secured a 50% stake. The ownership further diversified in 2017 when Jiangsu Yuyue Technology Development Co., Ltd. invested RMB 5.638 billion for a 10% stake in Baiyao Holdings, becoming its third-largest shareholder. This restructuring resulted in Yunnan SASAC holding 45%, New Huadu holding 45%, and Jiangsu Yuyue holding 10% of Baiyao Holdings. The process concluded on July 3, 2019, with Yunnan Baiyao merging with Baiyao Holdings via a share issuance to its three principal shareholders, a transaction valued at RMB 54.48 billion, thereby completing its overall listing.

These ownership adjustments have been instrumental in shaping the company's strategic direction and governance framework, with the aim of fostering greater efficiency and market responsiveness through a more balanced shareholder base. Understanding the Mission, Vision & Core Values of Yunnan Baiyao Group provides further context to how these stakeholders influence the company's operations.

Key Ownership Dynamics

As of early 2025, the ownership structure reflects a significant blend of state and private interests. The three largest shareholders collectively command a substantial portion of the company's shares.

• State and individual investors collectively held 29% of shares in 2024.
• Private companies accounted for 35% of the ownership in 2024.
• The three largest shareholders controlled 58% of the company's shares in 2024.
• The company is publicly traded on the A-share market.

Yunnan Baiyao Group PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors for Yunnan Baiyao Group Co., Ltd. is structured to oversee the company's operations, reflecting its unique blend of state and private ownership. As of the year ended December 31, 2024, the board includes key executive and non-executive members, as well as independent directors, all contributing to the company's governance framework. The composition aims to balance diverse stakeholder interests, a direct outcome of its mixed-ownership reform.

Mr. Zhang Wenxue holds the position of Chairman of the Executive Board. Mr. Dong Ming serves as Vice Chairman, Chief Executive Officer, and President, with his appointment as Vice Chairman dating back to August 26, 2024, and as CEO/President since March 4, 2021. Other executive directors include Mr. Tang Ming, who is also a Chief Executive Officer, and Mr. Liu Zhouyang. The board also comprises non-executive directors such as Mr. Qian Yinghui and Mr. Huang Bin. Providing independent oversight are Dr. Cecilia Wai Bing Pang, Dr. Cheung Hoi Yu, and Mr. Wong Hin Wing, who serve as independent non-executive directors.

The company's mixed-ownership reform, initiated to foster market-oriented mechanisms and improve corporate governance, has led to a board structure that includes representatives from major shareholders. This reform aimed to create equity checks and balances, moving away from the absolute control of a single entity. The influence of significant stakeholders, such as state-backed entities and private investors like New Huadu Industrial Group, is evident in the board's composition. Recent changes in board membership, including resignations in May 2024 due to 'work adjustments,' follow earlier reports of a 'corruption case' and investigations into former executives, highlighting the dynamic governance environment. While specific details on voting power mechanisms like dual-class shares are not publicly detailed, the board's structure is shaped by the significant stakes held by its major shareholders, influencing decision-making and oversight. Understanding these dynamics is key to grasping the Growth Strategy of Yunnan Baiyao Group.

Board Governance and Shareholder Influence

The board composition of Yunnan Baiyao Group reflects its mixed-ownership status, balancing state and private interests. This structure is a result of reforms aimed at enhancing corporate governance and efficiency.

• Key leadership roles include Chairman, Vice Chairman, CEO, and President.
• The board features executive, non-executive, and independent non-executive directors.
• Recent board changes underscore the evolving governance landscape.
• Major shareholders' influence is a significant factor in board dynamics.

Yunnan Baiyao Group Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Yunnan Baiyao Group has seen significant shifts in its ownership and governance over the past few years. A notable event in early 2024 was the company's decision to cancel 12,599,946 repurchased shares. Concurrently, the State-owned Equity Management Company has been actively increasing its stake, acquiring 17,807,463 shares, which represents 0.9980% of the total share capital. This acquisition occurred through centralized bidding on the Shenzhen Stock Exchange between August 2024 and February 2025, with a total investment of approximately RMB 950.38 million. By the close of 2024, the company's total share capital was 1,784,262,603 shares, indicating a dynamic Yunnan Baiyao ownership landscape.

Leadership transitions have also been a key feature, with several prominent figures departing. In March 2023, Wang Minghui, who had served as chairman for 19 years, resigned, followed by the resignation of Chief Sales Officer and Senior Vice President Wang Jin in the same month. More recently, in May 2024, directors Chen Fashu, Lu Hongdong, and Chen Yanhui submitted their resignations. These departures have been linked to reports of a 'corruption case' and investigations into former executives, suggesting a period of internal restructuring and governance adjustments within the company.

Yunnan Baiyao Group is strategically positioned to capitalize on the growing Chinese medicinal materials market. This growth is fueled by increasing consumer interest in traditional remedies, rising healthcare expenditures, and supportive government policies for research and development. The company is focusing its investments on product innovation and expanding its global distribution network to achieve growth rates exceeding the market average. For the fiscal year ending December 31, 2024, the company reported strong financial performance, with net profit attributable to shareholders rising by 16% to 4.75 billion yuan, and revenue increasing by 2% to 39.98 billion yuan. These figures highlight the company's efforts to adapt its operational strategies and ownership structure to a changing market, while managing internal challenges and capitalizing on external opportunities, including its Target Market of Yunnan Baiyao Group.

Ownership Adjustments

The company has actively managed its share capital, including the cancellation of repurchased shares in early 2024. State-owned entities have also increased their holdings, indicating a evolving Yunnan Baiyao stock ownership structure.

Leadership and Governance

Recent years have seen significant leadership changes, with several high-profile executives resigning. These transitions occurred amidst reports of investigations, pointing to ongoing efforts to strengthen the Yunnan Baiyao company structure.

Market Position and Financials

Yunnan Baiyao is well-positioned to benefit from the expanding Chinese medicinal materials market. The company's financial performance in 2024 showed robust growth, with net profit up 16% and revenue up 2%.

Strategic Focus

The company is prioritizing investments in product innovation and global distribution. This strategy aims to drive above-market growth and enhance its competitive standing in the pharmaceutical sector.

Yunnan Baiyao Group Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔